← All trials
NCT05118776
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 18, 2021
- Primary completion
- Jul 16, 2023
- Completion date
- Sep 16, 2023
- First posted
- Nov 12, 2021
- Last posted
- Nov 18, 2021
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ascletis Pharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.